For the Inventor, By the Inventor

Enter assignee name

Seongnam, South Korea

Abl Bio Inc.

USPTO Granted Patents = 17

EPO Patents = 5

Trademarks = 2

Forward Citations = 13

Loading Chart...

Loading Chart...

108 inventors (with patents filed for the assignee):

Yangsoon Lee (9 out of 10 patents)

Byungje Sung (8 out of 9 patents)

Eunsil Sung (8 out of 9 patents)

4. Yeunju Kim (8 out of 8 patents)

5. Hyejin Chung (8 out of 8 patents)

6. Eunyoung Park (7 out of 8 patents)

7. Youngdon Pak (7 out of 7 patents)

8. Jinhyung Ahn (6 out of 6 patents)

9. Kyungjin Park (6 out of 6 patents)

10. Donghoon Yeom (6 out of 6 patents)

11. Juhee Kim (5 out of 23 patents)

12. Sang Hoon Lee (5 out of 39 patents)

13. Daehae Song (5 out of 5 patents)

14. Yong-Gyu Son (5 out of 5 patents)

15. Jaehyun Eom (5 out of 5 patents)

17 patents: Sort by Forward Citations

1. 12624110 - ANTIBODY TO INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF1R) AND RELATED COMPOSITIONS AND USES (2026-05-12),

2. 12577314 - ANTI-BCMA/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF (2026-03-17),

3. 12252541 - Anti-BCMA antibody and use thereof (2025-03-18),

4. 12240913 - Anti-HER2/anti-4-1BB bispecific antibody and use thereof (2025-03-04),

5. 12195538 - Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof (2025-01-14),

6. 12195537 - Anti-4-1BB antibody and use thereof (2025-01-14),

7. 12173070 - Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof (2024-12-24),

8. 12168690 - Anti-EGFR/anti-4-1BB bispecific antibody (2024-12-17),

9. 12122830 - Anti-ROR1 antibody and use thereof (2024-10-22),

10. 12071483 - Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof (2024-08-27),

11. 12049493 - Anti-alpha-synuclein antibodies and uses thereof (2024-07-30),

12. 11891445 - Anti-B7-H3 antibody and use thereof (2024-02-06),

13. 11707533 - Antibody-drug conjugate comprising antibody against human ROR1 and use for the same (2023-07-25),

14. 11261259 - Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof (2022-03-01),

15. 10184010 - Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof (2019-01-22),

Abl Bio Inc. is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. Our team of experts is dedicated to advancing cutting-edge research and bringing new treatments to patients in need. Through our proprietary technology and strategic partnerships, we aim to make a meaningful impact on healthcare and improve outcomes for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

17 Patents

#43 in Seongnam

#719 in South Korea

#35,824 in the World

Seongnam, South Korea

Abl Bio Inc.

Forward Citations = 13

108 inventors:

Yangsoon Lee (9 out of 10 patents)

Byungje Sung (8 out of 9 patents)

Eunsil Sung (8 out of 9 patents)

4. Yeunju Kim (8 out of 8 patents)

5. Hyejin Chung (8 out of 8 patents)

Please report any incorrect information to [email protected]

Loading…